Body Handbook Catalogue Profile Ranking
Screening BODY HANDBOOK
Screening Β· Β§98
ApoB and Lipoprotein(a)
Your annual cholesterol panel can read "fine" while missing the two numbers that predict a heart attack best. ApoB counts the disease-causing particles themselves, not the cholesterol inside them. Lp(a) is a particle you inherit at birth that drives heart attacks and stiff valves, and never shows up on that panel. Here's what you didn't know you didn't know: about one adult in five runs a high Lp(a) and has no idea. One blood draw catches both, and Lp(a) only needs measuring once.
Screen Β· Once Evidence Strong Chapter Screening

ApoB counts particles; LDL only weighs their cargo. When both are tracked against future heart attacks in the same people, ApoB wins every time: nine head-to-head studies, ApoB the better predictor in all nine 1. In nearly 400,000 people, the LDL signal all but vanished once ApoB was accounted for 2.

Lp(a) is set by one gene and barely moves after that. The higher it is, the higher your coronary risk, in a straight line 3. People who inherit the high-Lp(a) gene get more heart attacks in exact proportion, the cleanest causal evidence biology offers 4. It also roughly doubles the odds of a calcified, leaky aortic valve 5. Diet, exercise, and statins don't touch it 6.

This is why "normal" labs still end in a parking-lot heart attack. Over a billion people carry Lp(a) above the risk threshold and mostly find out only after the first event 6. Up to a third of people on a statin hit a green-zone LDL while their ApoB stays over target: same arterial damage, congratulated for it 7.

At your next blood draw, add two tests to the usual panel. No fasting, both routine at any major lab.

Lp(a) almost never needs a retest. ApoB shifts with treatment, so re-check it when you start or change a lipid drug.

The result changes a decade of your life. For four readers in five it's reassurance for life: Lp(a) under the line, one less hidden number. For the fifth, a high result before forty pulls every downstream move a decade earlier: tighter ApoB targets, blood pressure watched sooner, family tested, first in line when the new Lp(a)-lowering drugs clear their trials 8. What it buys is the heart attack that doesn't happen in your fifties.

The fine print β€” when to skip it, and what people get wrong
  • "My LDL is fine, so I'm fine." About a quarter of adults have a normal LDL and an elevated ApoB, usually with belly weight, high triglycerides, or pre-diabetes 1.
  • "I'll lower Lp(a) with diet and exercise." You can't; only PCSK9 inhibitors nudge it, about 25% 9.
  • "The 50 mg/dL threshold fits everyone." It came from White European data; treat a borderline result more seriously if you're Black or South Asian 10.
  • The old assay. Mass-based mg/dL tests misread by particle size; ask for the nmol/L monoclonal assay 11.
  • Tested while sick. Infection shifts both markers; if a result looks off, retest a month later.

None. Both run on the same draw as any other lab; only an acute illness skews them temporarily.

References
  1. 1Sniderman AD, Thanassoulis G, Glavinovic T, et al. (2019). Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiology. link
  2. 2Marston NA, Giugliano RP, Melloni GEM, et al. (2022). Association of apolipoprotein B-containing lipoproteins and risk of myocardial infarction in individuals with and without atherosclerosis: distinguishing between particle concentration, type, and content. JAMA Cardiology. link
  3. 3Erqou S, Kaptoge S, Perry PL, et al. (Emerging Risk Factors Collaboration) (2009). Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA. link
  4. 4Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG (2009). Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA. link
  5. 5Thanassoulis G, Campbell CY, Owens DS, et al. (2013). Genetic associations with valvular calcification and aortic stenosis. New England Journal of Medicine. link
  6. 6Kronenberg F, Mora S, Stroes ESG, et al. (2022). Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement. European Heart Journal. link
  7. 7Wilkinson MJ, Lepor NE, Michos ED, et al. (2024). Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology. link
  8. 8O'Donoghue ML, Rosenson RS, Gencer B, et al. (2022). Small interfering RNA to reduce lipoprotein(a) in cardiovascular disease (OCEAN(a)-DOSE). New England Journal of Medicine. link
  9. 9O'Donoghue ML, Fazio S, Giugliano RP, et al. (2019). Lipoprotein(a), PCSK9 inhibition, and cardiovascular risk. Circulation. link
  10. 10ParΓ© G, Γ‡aku A, McQueen M, et al. (2019). Lipoprotein(a) levels and the risk of myocardial infarction among 7 ethnic groups. Circulation. link
  11. 11Marcovina SM, Albers JJ (2022). Lipoprotein(a) measurement issues: are we making a mountain out of a molehill? Atherosclerosis. link
Β·
98